{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:16:24Z","timestamp":1787242584443,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science,Japan","doi-asserted-by":"crossref","award":["JSPS KAKENHI (22K15693)"],"award-info":[{"award-number":["JSPS KAKENHI (22K15693)"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There have been very few real-world studies reported in the literature solely focusing on fremanezumab in Asia. This study aimed to evaluate the efficacy and safety of fremanezumab in a real-world setting in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This single-centered, observational, retrospective study examined patients with migraines who received four doses of fremanezumab between December 2021 and August 2022 at Keio University Hospital. We assessed the changes in monthly migraine days, responder rates, and migraine-associated symptoms, as well as injection site reactions and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Twenty-nine patients were enrolled, wherein 79.3% were women. Compared with those at baseline, the monthly migraine days decreased by 5.9\u00a0days at 4\u00a0months. The 50% responder rate was 55.2% at 4\u00a0months. A total of 57.9%, 47.8%, and 65.0% of patients showed improvement in the severity of photophobia, phonophobia, and nausea\/vomiting, respectively. Moreover, injection site reactions were the most common adverse events (55.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fremanezumab is effective and safe for migraine prevention in Japan. Fremanezumab also improved migraine-associated symptoms in half of the patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-023-03449-3","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T04:02:24Z","timestamp":1699934544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study"],"prefix":"10.1186","volume":"23","author":[{"given":"Seiya","family":"Ohtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"3449_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:954\u201376.","journal-title":"Lancet Neurol."},{"key":"3449_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15\u201322.","journal-title":"Cephalalgia"},{"key":"3449_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD 2019. J Headache Pain. 2020;21:137.","journal-title":"J Headache Pain."},{"key":"3449_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/0333102418779544","volume":"39","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Goadsby PJ. Discovery of CGRP in relation to migraine. Cephalalgia. 2019;39:331\u20132.","journal-title":"Cephalalgia"},{"key":"3449_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23:67.","journal-title":"J Headache Pain"},{"key":"3449_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999\u20132008.","journal-title":"JAMA"},{"key":"3449_CR7","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340.","journal-title":"Lancet"},{"key":"3449_CR8","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113\u201322.","journal-title":"N Engl J Med"},{"key":"3449_CR9","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim B, Igarashi H, Hirata K, Takeshima T, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1092\u2013101.","journal-title":"Headache"},{"key":"3449_CR10","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1102\u201311.","journal-title":"Headache"},{"key":"3449_CR11","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2147\/JPR.S393896","volume":"16","author":"K Saigoh","year":"2023","unstructured":"Saigoh K, et al. Fremanezumab for episodic migraine prevention in Japanese patients: subgroup analysis from two international trials. J Pain Res. 2023;16:1673\u201382.","journal-title":"J Pain Res"},{"key":"3449_CR12","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2147\/JPR.S393854","volume":"16","author":"K Saigoh","year":"2023","unstructured":"Saigoh K, et al. Fremanezumab for chronic migraine prevention in japanese patients: subgroup analysis from two international trials. J Pain Res. 2023;16:1311\u20139.","journal-title":"J Pain Res"},{"key":"3449_CR13","unstructured":"Ministry of Health, Labour and Welfare. Guidelines for promotion of optimal use of fremanezumab. Accessed 24 February 2023; published 2021."},{"key":"3449_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, d\u2019Onofrio F, Albanese M, Cetta I, et al. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022;23:46.","journal-title":"J Headache Pain"},{"key":"3449_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10194-023-01561-w","volume":"24","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Egeo G, Aurilia C, Torelli P, Finocchi C, d\u2019Onofrio F, et al. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. J Headache Pain. 2023;24:30.","journal-title":"J Headache Pain"},{"key":"3449_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, et al. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol. 2022;22:512.","journal-title":"BMC Neurol"},{"key":"3449_CR17","doi-asserted-by":"publisher","unstructured":"Ito Y, Mitsufuji T, Okada M, Fujita S, Yokoyama R, Kawasaki H, Yamamoto T. Early Effect of Calcitonin Generelated Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study. Intern Med; 2023. https:\/\/doi.org\/10.2169\/internalmedicine.1471-22. Epub ahead of print.","DOI":"10.2169\/internalmedicine.1471-22"},{"key":"3449_CR18","doi-asserted-by":"publisher","first-page":"333102423117764","DOI":"10.1177\/03331024231177649","volume":"43","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, et al. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan. Cephalalgia. 2023;43:3331024231177649.","journal-title":"Cephalalgia"},{"key":"3449_CR19","doi-asserted-by":"publisher","first-page":"1220285","DOI":"10.3389\/fneur.2023.1220285","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, et al. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285.","journal-title":"Front Neurol"},{"key":"3449_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K, et al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain. 2023;24:23.","journal-title":"J Headache Pain"},{"key":"3449_CR21","unstructured":"Muramatsu K, Seiryo N, Muramatsu Y, Miyaoka H, Fuse K, Yoshine F, et al. Validation and utility of Japanese version of the GAD-7. PANMINERVA medica. Admin Book 20th World Congress on Psychosomatic Medicine, vol 51; 2009. p. 79."},{"key":"3449_CR22","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.3389\/fpsyg.2018.01741","volume":"9","author":"S Doi","year":"2018","unstructured":"Doi S, Ito M, Takebayashi Y, Muramatsu K, Horikoshi M. Factorial validity and invariance of the 7-item generalized anxiety disorder scale (GAD-7) among populations with and without self-reported psychiatric diagnostic status. Front Psychol. 2018;9:1741.","journal-title":"Front Psychol"},{"key":"3449_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.genhosppsych.2018.03.007","volume":"52","author":"K Muramatsu","year":"2018","unstructured":"Muramatsu K, Miyaoka H, Kamijima K, Muramatsu Y, Tanaka Y, Hosaka M, et al. Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. Gen Hosp Psychiatry. 2018;52:64\u20139.","journal-title":"Gen Hosp Psychiatry"},{"key":"3449_CR24","doi-asserted-by":"publisher","first-page":"e2260","DOI":"10.1002\/brb3.2260","volume":"11","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S. Predictors of response to erenumab after 12 months of treatment. Brain Behav. 2021;11:e2260.","journal-title":"Brain Behav"},{"key":"3449_CR25","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/ene.15236","volume":"29","author":"C Zecca","year":"2022","unstructured":"Zecca C, Cargnin S, Schankin C, Giannantoni NM, Viana M, Maraffi I, et al. Clinic and genetic predictors in response to erenumab. Eur J Neurol. 2022;29:1209\u201317.","journal-title":"Eur J Neurol"},{"key":"3449_CR26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102419885905","volume":"40","author":"JL Brandes","year":"2020","unstructured":"Brandes JL, Kudrow D, Yeung PP, Sakai F, Aycardi E, Blankenbiller T, et al. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine. Cephalalgia. 2020;40:470\u20137.","journal-title":"Cephalalgia"},{"key":"3449_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/ane.13599","volume":"145","author":"A L\u00f3pez-Bravo","year":"2022","unstructured":"L\u00f3pez-Bravo A, Oliveros-Cid A, Sevillano-Orte L. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: a real-life experience in migraine. Acta Neurol Scand. 2022;145:669\u201375.","journal-title":"Acta Neurol Scand"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03449-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03449-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03449-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T04:03:16Z","timestamp":1699934596000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03449-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3449"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03449-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ethics Committee of the Keio University School of Medicine (approval number: 20211144). Patients were informed about this observational study via the institute\u2019s website, and they could opt out of the study. The need for informed consent was waived by the Ethics Committee of the Keio University School of Medicine, in accordance with national regulations (Ethical Guidelines for Medical and Biological Research Involving Human Subjects). All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TT is a consultant\/advisor and\/or served as advisory board for Otsuka, Eli Lilly, Amgen, Pfizer and Teijin. TT received speaker honoraria from Otsuka, Eli Lilly, Daiichi Sankyo, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, Takeda, and Santen Pharmaceutical and research funding from Eli Lilly and Tsumura outside the submitted work. JN received honoraria and research scholarships from Amgen and Daiichi Sankyo. Other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"404"}}